Literature DB >> 27540904

A prospective randomized trial of the optimal dose of mannitol for intraoperative brain relaxation in patients undergoing craniotomy for supratentorial brain tumor resection.

Hyungseok Seo1, Eugene Kim2, Haesun Jung1, Young-Jin Lim1, Jin Wook Kim3, Chul-Kee Park3, Young-Bem Se3, Young-Tae Jeon4, Jung-Won Hwang4, Hee-Pyoung Park4.   

Abstract

OBJECTIVE Mannitol is used intraoperatively to induce brain relaxation in patients undergoing supratentorial brain tumor resection. The authors sought to determine the dose of mannitol that provides adequate brain relaxation with the fewest adverse effects. METHODS A total of 124 patients were randomized to receive mannitol at 0.25 g/kg (Group A), 0.5 g/kg (Group B), 1.0 g/kg (Group C), and 1.5 g/kg (Group D). The degree of brain relaxation was classified according to a 4-point scale (1, bulging; 2, firm; 3, adequate; and 4, perfectly relaxed) by neurosurgeons; Classes 3 and 4 were considered to indicate satisfactory brain relaxation. The osmolality gap (OG) and serum electrolytes were measured before and after mannitol administration. RESULTS The brain relaxation score showed an increasing trend in patients receiving higher doses of mannitol (p = 0.005). The incidence of satisfactory brain relaxation was higher in Groups C and D than in Group A (67.7% and 64.5% vs 32.2%, p = 0.011 and 0.022, respectively). The incidence of OG greater than 10 mOsm/kg was also higher in Groups C and D than in Group A (100.0% in both groups vs 77.4%, p = 0.011 for both). The incidence of moderate hyponatremia (125 mmol/L ≤ Na+ < 130 mmol/L) was significantly higher in Group D than in other groups (38.7% vs 0.0%, 9.7%, and 12.9% in Groups A, B, and C; p < 0.001, p = 0.008, and p = 0.020, respectively). Hyperkalemia (K+ > 5.0 mmol/L) was observed in 12.9% of patients in Group D only. CONCLUSIONS The higher doses of mannitol provided better brain relaxation but were associated with more adverse effects. Considering the balance between the benefits and risks of mannitol, the authors suggest the use of 1.0 g/kg of intraoperative mannitol for satisfactory brain relaxation with the fewest adverse effects. Clinical trial registration no.: NCT02168075 ( clinicaltrials.gov ).

Entities:  

Keywords:  ICP = intracranial pressure; OG = osmolality gap; brain relaxation; brain tumor; hyponatremia; mannitol; oncology; osmolality gap

Mesh:

Substances:

Year:  2016        PMID: 27540904     DOI: 10.3171/2016.6.JNS16537

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  4 in total

1.  Risk Factors Associated With Inadequate Brain Relaxation in Craniotomy for Surgery of Supratentorial Tumors.

Authors:  Natalia Pérez de Arriba; Aida Antuña Ramos; Vanesa Martin Fernandez; Maria Del Carmen Rodriguez Sanchez; Jose Ricardo Gonzalez Alarcon; Marco Antonio Alvarez Vega
Journal:  Cureus       Date:  2022-05-31

2.  Clinical effectiveness of hypertonic sodium lactate infusion for intraoperative brain relaxation in patients undergoing scheduled craniotomy for supratentorial brain tumor resection: A study protocol of a single center double-blind randomized controlled phase II pilot trial.

Authors:  Guillaume Besch; Anne-Laure Parmentier; Francis Berthier; Hélène Jaeg; Julien Villeneuve; Fethi Hammoudi; Nans Scaringella; Anne-Laure Clairet; Lucie Vettoretti; Gilles Chopard; Laurent Thines; David Ferreira; Emmanuel Samain; Sebastien Pili-Floury
Journal:  Medicine (Baltimore)       Date:  2022-10-07       Impact factor: 1.817

3.  Brain-Relaxing Effect of Different Diuretic Regimens in Supratentorial Tumor Surgery: A Comparative Study Guided by Optic Nerve Sheath Diameter.

Authors:  Mohamed Adel Aboelela; Alrefaey Kandeel Alrefaey
Journal:  Anesth Essays Res       Date:  2021-03-22

4.  Comparison of the effects of 7.2% hypertonic saline and 20% mannitol on electrolyte and acid-base variables in dogs with suspected intracranial hypertension.

Authors:  Sabrina N Hoehne; Ivayla D Yozova; Beatriz Vidondo; Katja N Adamik
Journal:  J Vet Intern Med       Date:  2020-11-25       Impact factor: 3.175

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.